Agilent, GKPC-020, AdvanceBio InstantPC CHO mAb N-glycan library (formerly ProZyme)

AdvanceBio InstantPC CHO mAb N-glycan library (formerly ProZyme). Library consists of neutral fucosylated complex biantennary and high mannose N-glycans present in many CHO derived monoclonal antibodies (mAbs). The reducing termini are derivatized with the fluorescent dye, InstantPC. The source protein is also available separately (p/n GKP-020, 0.25 mg), or together with this GKPC-020 InstantPC labeled N-glycan standard library as p/n GKPC-020-P.

Specifications:
Label: InstantPC
Unit: 25 Injections

**********The following product description is generated by AI and is for reference only. If you have any questions, please contact customer service.**********
The AdvanceBio InstantPC CHO mAb N-glycan library offers a comprehensive, ready-to-use reference standard for detailed analysis of N-linked glycans derived from Chinese Hamster Ovary (CHO) expressed monoclonal antibodies. This library enables precise identification, characterization, and quantitation of released N-glycans labeled with InstantPC dye, ensuring enhanced fluorescence sensitivity and chromatographic resolution. Researchers utilize this standard for biopharmaceutical development, glycoprofiling, and quality control in monoclonal antibody production, streamlining method development and validation for glycan analysis workflows. The product supports comparative studies and batch consistency monitoring, and is widely adopted in both academic and regulated laboratory environments. Compatible with Agilent LC and LC-MS systems as well as other HPLC and UHPLC platforms, the library is an ideal complement to Agilent AdvanceBio Glycan Mapping columns and associated sample preparation kits. Its robust performance facilitates reproducible results in applications including biosimilar characterization, glycan structure elucidation, and therapeutic antibody glycoengineering studies. The library is an essential tool for scientists seeking high-confidence glycan identification, supporting regulatory compliance and innovative research across the biotherapeutics sector.